Clinical Trial Update: Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neratinib plus capecitabine in HER2-negative metastatic breast cancer with brain metastases and abnormal HER2 signaling. Recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• neratinib (neratinib)

Snippet

Sponsor: University of Rochester | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING